ABSTRACT
Introduction: In patients with type 2 diabetes mellitus,dapagliflozin, the sodium–glucose cotransporter 2 inhibitorhas been shown to improve diabetic control and reduceblood pressure. The main objective of the study is to evaluateefficacy of SGLT2 inhibitor dapagliflozin on markers of macroand micro vascular complications as add on treatment in type2 diabetes patients in real world set up.Material and methods: This was an observational studydone in real world set up. 87 patients were initially selectedamong whom 5 patients were lost in follow up and 2 patientswere excluded as they discontinued the study medicine. 80patients who received dapagliflozin 10 mg once daily for 24weeks in addition to metformin 1000 mg and glimepiride2 mg combination. Changes in both systolic and diastolicblood pressure, HbA1c (Glycated haemoglobin), fasting andpostprandial plasma glucose, lipid profile (including Totalcholesterol, Triglycerides, LDL and HDL cholesterol), serumcreatinine, serum microalbuminuria, eGFR and HOMA IRwere noted. All pathological test was executed at NABLaccredited lab.Results: After 24 weeks from baseline there was almost1.4% reduction in HbA1c. Fasting and post prandial bloodglucose was significantly reduced within 24 weeks. HOMAIR was significantly changed. No marked changes were seenin serum creatinine, microalbuminuria and eGFR. There wasa favorable reduction in lipid profile.Conclusion: Dapagliflozin has a very potent glycemic effectand has a significant impact on markers of macro and microvascular complications as add on treatment in type 2 diabetespatients. In conclusion it can be stated that early addition ofdapagliflozin therapy not only helps T2DM patients to achievetheir glycemic control but also prevents further macro andmicro vascular complications by reducing markers and riskfactors.